Do you actually read the post. I stated that th
Post# of 72440
I stated that the other phase 3 costs (not necessarily other mid-stage trials)
will be comparable in cost.
All the PHASE 3 trials will require a much larger number of participants than these smaller phase 2 trials. They will need to be blinded, not open label. A Kevetrin PHASE 3 would be much more expensive than for B-ABSSSI. It would be longer, more extensive for each patient, more demanding on clinicians and the CRO.
You disagree?